API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
Details:
ABBV-951 (Foslevodopa/Foscarbidopa) is a solution of levodopa and carbidopa prodrugs for continuous subcutaneous infusion that is being investigated for the treatment of advanced Parkinson's disease in patients whose motor symptoms are not controlled by oral medications.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: ABBV-951
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2021
Details:
Merz Therapeutics will purchase substantially all of the assets of Acorda, including the rights to Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), and Fampyra (dalfampridine). INBRIJA is used when needed for OFF episodes in adults with Parkinson's disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Merz Pharma
Deal Size: $185.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 02, 2024
Details:
Through the licensing agreement, Zambon will commercialize IPX203, an oral formulation of carbidopa/levodopa extended-release capsules designed for the treatment of Parkinson’s disease.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: IPX203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Zambon Group SpA
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement February 27, 2024
Details:
IPX203 (carbidopa/levodopa) is a novel, oral extended-release capsule formulation. It is being evaluated in phase 3 clinical trials for the treatment of parkinson's disease with motor fluctuations.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: IPX203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 08, 2024
Details:
Levodopa Cyclops™ is a levodopa dry powder inhaler which is being evaluated in phase 2 clinical trials for the fast and reliable relief of OFF episodes in Parkinson’s disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Levodopa Cyclops
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Details:
INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
ND0612 is an investigative drug-device combination therapy – a 24 hours/day, continuous subcutaneous infusion of liquid levodopa/carbidopa (LD/CD) for people with Parkinson’s disease (PD) experiencing motor fluctuations.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: ND0612
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NeuroDerm
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 28, 2023
Details:
IPX203 is a novel, oral formulation of contains immediate-release granules and extended-release capsules designed for the treatment of Parkinson’s disease.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: IPX203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 03, 2023
Details:
The collaboration aims to provide INBRIJA® in China. Inbrija (levodopa) is indicated in the United States for the intermittent treatment of episodic motor fluctuations in adult patients with Parkinson's disease treated with a levodopa/dopa-decarboxylase inhibitor.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chance Pharmaceuticals
Deal Size: $144.0 million Upfront Cash: $2.5 million
Deal Type: Agreement May 08, 2023
Details:
Through the acquisition, Navamedic will broaden its product portfolio, including Flexilev, containing two active substances, levodopa and carbidopa and to support patients suffering from medical conditions, such as Parkinson's disease.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: Flexilev
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Navamedic
Deal Size: $9.3 million Upfront Cash: $9.3 million
Deal Type: Acquisition April 24, 2023
Details:
Carbidopa and levodopa targets dopamine receptor, it is being approved for the treatment of motor fluctuations in patients with advanced parkinson's disease.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: Sinemet-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2023
Details:
The funds will be used to develop lead program Levodopa Cyclops™ for US and EEA marketing, of which early clinical studies already demonstrated very rapid onset of action in combatting OFF-episodes in Parkinsons' disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Levodopa Cyclops
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Boost-UP Foundation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing April 03, 2023
Details:
Through the acquisition, Navamedic will broaden its product portfolio and to support patients suffering from medical conditions, such as Parkinson's disease, including Flexilev, containing two active substances, levodopa and carbidopa.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: Flexilev
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Navamedic
Deal Size: $7.2 million Upfront Cash: $7.2 million
Deal Type: Acquisition March 29, 2023
Details:
Inbrija (levodopa) is levodopa/dopa-decarboxylase inhibitor, it is converted to dopamine replacement agent for the intermittent treatment of episodic motor fluctuations of Parkinson disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acorda Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2023
Details:
ND0612 is a continuous, subcutaneous infusion levodopa/carbidopa delivery system under development for patients with Parkinson's disease (PD) and motor fluctuations.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: ND0612
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 09, 2023
Details:
INBRIJA® (levodopa) is approved for intermittent treatment of OFF episodes in adults with Parkinson’s disease treated with carbidopa. INBRIJA utilizes ARCUS® pulmonary delivery system, a technology platform designed to deliver medication through inhalation.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Acorda Therapeutics
Deal Size: $10.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 05, 2023
Details:
IPX203 (levodopa) is a novel, oral formulation of CD/LD extended-release capsules designed for the treatment of Parkinson’s disease. IPX203 contains immediate-release granules and extended-release beads.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: IPX203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Infudopa IntraV™ (DIZ101) is a levodopa-carbidopa solution aimed to be administered intravenously using infusion pumps to inpatients who cannot receive oral administration of levodopa when being the subject of surgery with general anesthesia.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: Infudopa IntraV
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
The DopaFuse Delivery System is a patented, intra-oral system that continuously and noninvasively delivers levodopa and carbidopa at a controlled rate for patients with PD.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Clintrex Research Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 01, 2022
Details:
IPX203 (Levodopa), is a novel, oral formulation of CD/LD extended-release capsules designed for the treatment of Parkinson’s disease. IPX203 contains immediate-release granules and extended-release coated beads.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: IPX-203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 31, 2022
Details:
KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin, however the company decided to discontinue its phase 2 trial after through evaluation of global regulatory landscape & potential timelines for market entry.
Lead Product(s): KW-6356,Etilevodopa
Therapeutic Area: Neurology Product Name: KW-6356
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
INBRIJA® 33 mg (levodopa inhalation powder, hard capsules) is indicated in the EU for the intermittent treatment of episodic motor uctuations (OFF episodes) in adult patients with Parkinson’s disease treated with a levodopa/dopa-decarboxylase inhibitor.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Huayi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement June 16, 2022
Details:
Under the terms of the agreements, Acorda will receive a significant percentage of the selling price of INBRIJA in Latin America in exchange for supply of the product. Biopas plans on seeking marketing authorization in all countries to make Inbrija available for patients.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Biopas Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 11, 2022
Details:
Long-term safety data from the Phase 2b BeyoND study demonstrated a positive ND0612, an investigational drug-device combination safety and tolerability profile beyond one year in people with Parkinson's disease.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: ND0612
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 04, 2022
Details:
In the trial, IPX-203 showed statistically significant improvement in “Good On” time compared to immediate release CD/LD, when dosed on average three times a day compared to five times a day for immediate release CD/LD.
Lead Product(s): Carbidopa,Etilevodopa
Therapeutic Area: Neurology Product Name: IPX-203
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 24, 2022
Details:
Proceeds from the financing will enable Intrance to initiate pivotal U.S. clinical trials for the company’s lead product, Lecigon® (in the Nordic countries and European markets) for enteral infusion (light weight infusion pump) in advanced Parkinson’s disease patients.
Lead Product(s): Carbidopa,Etilevodopa,Entacapone
Therapeutic Area: Neurology Product Name: Lecigon
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Erik Selin
Deal Size: $17.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 04, 2022
Details:
Under the agreement, ESTEVE will have the exclusive distribution rights to INBRIJA in Germany and ACORDA will supply the product to ESTEVE. ESTEVE expects to launch INBRIJA in Germany by mid-2022.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Huayi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: $5.6 million
Deal Type: Agreement November 09, 2021
Details:
The DopaFuse System consists of an oral retainer, its case, and a prefilled, single-use drug container that continuously releases an investigational levodopa and carbidopa paste in the back of the mouth.
Lead Product(s): Etilevodopa,Carbidopa
Therapeutic Area: Neurology Product Name: DopaFuse
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2021
Details:
Under the terms of the supply agreement, ACORDA will receive a significant double-digit percent of the selling price of INBRIJA in Spain in exchange for supply of the product.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Esteve Huayi Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement July 22, 2021
Details:
The novel gel formulation is of the three established Parkinson's active ingredients levodopa, carbidopa and entacapone has a positive effect on the bioavailability of levodopa in the body.
Lead Product(s): Etilevodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 15, 2021
Details:
Catalent has also entered into a long-term supply agreement with Acorda Therapeutics to continue commercial manufacture of INBRIJA® (levodopa inhalation powder) from the Chelsea facility.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 15, 2021
Details:
Under the terms of the agreement Catalent will manufacture and package INBRIJA for Acorda, ensuring an uninterrupted drug supply for Acorda’s patients and continued adherence to best-in-class manufacturing quality and safety standards.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Inbrija
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Catalent Pharma Solutions
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Agreement January 13, 2021
Details:
By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
Lead Product(s): Etilevodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2020
Details:
LiberaTx, an NTU-incubated start-up is now commercialising new slow-release pill that delivers L-dopa over a period of 24 hours, which could help to alleviate symptoms related to Parkinson’s disease.
Lead Product(s): Etilevodopa
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2020